Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Biodesix, Inc. (NASDAQ:BDSX) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $32.50.

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Canaccord Genuity Group set a $20.00 price objective on shares of Biodesix and gave the stock a “buy” rating in a report on Friday, September 19th.

Biodesix Trading Up 1.7%

Shares of BDSX stock opened at $7.87 on Thursday. The company has a market capitalization of $62.65 million, a PE ratio of -1.42 and a beta of 0.98. Biodesix has a 52-week low of $3.44 and a 52-week high of $32.20. The business’s fifty day moving average is $7.34 and its 200 day moving average is $7.14. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Biodesix has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Biodesix will post -0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jack W. Schuler purchased 142,045 shares of the company’s stock in a transaction on Friday, September 19th. The stock was purchased at an average price of $7.04 per share, with a total value of $999,996.80. Following the completion of the purchase, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. This trade represents a 11.47% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders bought 334,836 shares of company stock worth $2,611,362 and sold 300 shares worth $2,286. 30.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Biodesix

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd grew its holdings in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the last quarter. Blair William & Co. IL boosted its position in Biodesix by 33.3% during the 1st quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock valued at $78,000 after buying an additional 31,000 shares during the period. Oracle Investment Management Inc. bought a new stake in Biodesix in the 3rd quarter worth $113,000. Millennium Management LLC purchased a new position in shares of Biodesix in the third quarter valued at about $113,000. Finally, Monashee Investment Management LLC raised its stake in shares of Biodesix by 15.7% during the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock valued at $2,532,000 after acquiring an additional 549,121 shares during the last quarter. 20.96% of the stock is owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.